Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Pre-clinical data have shown that osteoprotegerin (OPG) inhibits osteoclast function and therefore plays an important role in bone remodelling. This study aimed to evaluate the clinical value of serum OPG. Do higher OPG serum levels reflect decreased bone resorption and perhaps higher bone mass in women? Serum OPG levels were measured in 177 healthy women (aged 17-85 years) and in 48 untreated patients (mean age 71 +/- 5) with established osteoporosis, and related to age, bone mass, markers of bone turnover and, in the case of patients with osteoporosis, to pre-existing vertebral fractures. In healthy women OPG levels showed a positive correlation with age (r = 0.25, p < 0.001) but not to bone mass or markers of bone turnover. In women with osteoporosis, however, there was a strong relationship between serum OPG and markers of bone turnover (serum c-terminal crosslinked telopeptides of thpe I collagen (sCTX): r = +0.82, p < 0.0001; osteocalcin (OC): r = +0.69, p < 0.0001), with patients who had higher levels of bone-turnover markers showing higher serum levels of OPG. After adjustment for bone mass and bone markers, patients with pre-existing vertebral fractures had significantly lower serum OPG levels than patients without fractures (57 +/- 8 vs. 97 +/- 10 pg/ml, [mean +/- SE], p < 0.01). The age-dependent increase of OPG as an antiresorptive factor may reflect an insufficient paracrine mechanism of bone cells to compensate for bone loss in older age. In patients with osteoporosis, however, OPG correlated strongly with markers of bone turnover; this may point toward a higher level of RANKL/OPG expression in these patients. Finally, low OPG serum levels seem to be associated with vertebral fractures. We hypothesise that low OPG levels in preset conditions of bone turnover may indicate a higher risk of fracture in patients with osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [384]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“As OPG is expressed not only by osteoblasts but also in high concentrations by a variety of tissues [1, 2, 7, 8, 25] and is a key regulator of the immune system [1, 2, 26, 27], interpretation of OPG serum levels in a cohort of patients, some of whom are in poor health, may be difficult.”
BackgroundOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · cited 1×
“The importance of OPG may therefore be revealed only in the presence of pathological conditions or medication influencing bone metabolism [23, 24, 30, 31].”
BackgroundIsolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · cited 2×
“Osteoprotegerin (OPG) emerged as a bone “protector” from in vitro and pre-clinical work [1, 2, 6, 7, 9, 10, 11].”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 1×
“The importance of OPG may therefore be revealed only in the presence of pathological conditions or medication influencing bone metabolism [23, 24, 30, 31].”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650
Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.463 · Cited by 550
Browner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · cited 3×
“Further, other authors have proposed that women with very severe osteoporosis and very high markers of bone turnover could have very high OPG levels to protect against bone loss [13].”
BackgroundResultOsteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status1
Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., & Delmas, P. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7657 · Cited by 234
TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
Wong, B. R., Josien, R., & Choi, Y. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.6.715 · Cited by 232
Correlates of osteoprotegerin levels in women and men.
Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205 · cited 2×
“found an inverse relationship between OPG serum levels and bone mass in postmenopausal women [13], and recently published data showed similar findings in a cohort of healthy men [14].”
BackgroundResultHofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 169
Kanis, J. A. (1997) · Osteoporosis International · doi:10.1007/bf03194355 · Cited by 148
Morii, H., & Kanis, J. A. (1997) · Osteoporosis International · doi:10.1007/bf03194334 · Cited by 140
Hakeda, Y., Kobayashi, Y., Yamaguchi, K., Yasuda, H., Tsuda, E., Higashio, K., Miyata, T., & Kumegawa, M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9523 · Cited by 107
Makhluf, H. A., Mueller, S. M., Mizuno, S., & Glowacki, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2182 · Cited by 102
Molecular control of bone remodeling and osteoporosis
Kong, Y., & Penninger, J. M. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00178-9 · Cited by 100
Haas, M., Leko-Mohr, Z., Roschger, P., Kletzmayr, J., Schwarz, C., Domenig, C. M., Zsontsich, T., Klaushofer, K., Delling, G., & Oberbauer, R. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.31409 · Cited by 87
Fahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71
Self-citation(2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.12.2293 · Cited by 64
Kanis, J. А. (2016) · Osteoporosis and Bone Diseases · doi:10.14341/osteo201614-5 · Cited by 59
Fahrleitner, A., Prenner, G., Kniepeiss, D., Iberer, F., Tscheliessnigg, K., Piswanger-Soelkner, C., Obermayer-Pietsch, B. M., Leb, G., & Dobnig, H. (2002) · PubMed · Cited by 21
Self-citationLetter: More on adjusting serum Ca for protein.
Husdan, H., Rapoport, A., Locke, S., & Oreopoulos, D. G. (1976) · Clinical Chemistry · doi:10.1093/clinchem/22.6.0933a · Cited by 7
Research works printed but not linked: 2
- Bu R, McKeon RM, Cao L, Blair HC (2001) Osteoprotegerin (OPG) binds TNF family proteins including TNFα and protects osteoblasts from TNFα-induced apoptosis: a complementary function in addition to effects of OPG on osteoclast differentiation via RANKL. J Bone Miner Res 16 [Suppl 1]: S169 (Abstract)
- Holt MI, Baattrup A, Eriksen EF (2001) Expression of osteoclast differentiating factor (ODF, RANKL) and osteoprotegerin (OPG) in human bone: role of the bone remodeling compartment in the coupling between resorption and formation. J Bone Miner Res 16 [Suppl 1]: S364 (Abstract)
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Collin-Osdoby, P. (2004) · Circulation Research · doi:10.1161/01.res.0000149165.99974.12 · Cited by 473
Dimorphic effects of Notch signaling in bone homeostasis
Engin, F., Yao, Z., Yang, T., Zhou, G., Bertin, T., Jiang, M. M., Chen, Y., Wang, L., Zheng, H., Sutton, R. E., et al. (2008) · Nature Medicine · doi:10.1038/nm1712 · Cited by 413
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Goëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
Metadata
- Authors
- Fahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B.
- Affiliations
- University of Graz (AT)
- Venue
- Wiener Klinische Wochenschrift
- Published
- 2003-05
- Volume
- 115
- Issue
- 9
- Pages
- 291-297
- ISSN
- 0043-5325 (ISSN-L)
- 1613-7671
- OpenAlex
- W86347301
- Cited by
- 62
- References
- 33
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 2
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Wiener klinische Wochenschrift (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoprotegerin, osteoporosis, vertebral fractures, bone turnover markers, bone mass, RANKL/OPG pathway, osteocalcin, C-terminal telopeptide of type I collagen, bone resorption, women, aging
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Aging, Bone Diseases, Metabolic, Bone Resorption, Female, Fractures, Spontaneous, Glycoproteins, Humans, Middle Aged, Reference Values, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.